PT-141 (Bremelanotide / Vyleesi) 2026: Cost, Samples & Access for the FDA-Approved Sexual Desire Peptide
PT-141 — also called bremelanotide and marketed in the US as Vyleesi — is a synthetic melanocortin receptor agonist that acts on central nervous system pathways involved in sexual arousal. Unlike sildenafil (Viagra) or tadalafil (Cialis), which act on vascular tissue to produce mechanical erection, PT-141 acts on the brain's desire and arousal circuits. The mechanism is fundamentally different.
PT-141 was FDA-approved in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). It's administered via subcutaneous injection 45 minutes before anticipated activity, on demand rather than daily.
Off-label, PT-141 is increasingly used in men's sexual health protocols where the issue is desire and arousal rather than erectile function. It's also used in women off-label outside the on-label HSDD criteria. The clinical case is strongest in patients whose primary complaint is desire rather than mechanical function.
- 10 programs ranked
- Editor-reviewed
- Reader-verified
- Updated weekly
What's actually available: PT-141 (Bremelanotide) samples in 2026
Three paths for people typing “pt-141 (bremelanotide)samples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Vyleesi via specialty pharmacy (on-label HSDD) | On-label prescription routed through specialty pharmacy with manufacturer support. | $50-450 / dose with insurance and savings card | Premenopausal women with diagnosed HSDD meeting label criteria |
| Off-label telehealth (men's + women's sexual health) | Telehealth clinic prescribing off-label PT-141 for desire-focused complaints. | $200-400 / month subscription including 4-8 doses | Patients whose primary complaint is desire/arousal rather than mechanical erectile function |
| Specialty hormone clinic (off-label) | Specialty clinic prescribing PT-141 alongside broader hormone-optimization protocols. | $300-600 / month including consult + medication | Patients running broader hormone or peptide protocols who want PT-141 in the mix |
How PT-141 (Bremelanotide) samples actually work
Central vs peripheral mechanism
PT-141 acts on melanocortin-4 receptors in the central nervous system, particularly in the hypothalamus, which modulates sexual arousal pathways. This is fundamentally different from sildenafil and tadalafil, which act peripherally on vascular smooth muscle to increase blood flow. PT-141 produces desire and arousal centrally; it does not directly produce mechanical erection. For patients whose complaint is 'I have erections fine but no interest,' PT-141 addresses the actual problem; for patients whose complaint is 'I have desire but trouble achieving erection,' a PDE5 inhibitor is the right tool.
On-demand dosing convention
PT-141 is administered subcutaneously 45 minutes before anticipated activity. Effect lasts roughly 6-12 hours. It is not a daily preventative — it is dosed when needed. Most patients use 4-8 doses per month, with manufacturer's safety guidance limiting use to once per 24 hours and no more than 8 doses per month.
Why it's emerging in men's health protocols
ED treatment historically focused on PDE5 inhibitors because the largest patient segment had vascular ED. As clinical attention has shifted toward libido and desire complaints — particularly in patients on TRT, antidepressants, or with stress-related arousal complaints — PT-141 has filled a gap that PDE5 inhibitors don't address. Off-label use in men is increasingly mainstream in specialty hormone-optimization clinics.
PT-141 is a brain peptide, not a vascular drug. It works on the desire pathway, not the erection pathway. That makes it the wrong tool for some patients and exactly the right tool for others.
PT-141 (Bremelanotide) cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Vyleesi on-label, insured + savings | $50-200 | $50-450 per dose | On-label HSDD with commercial insurance + Vyleesi savings card. |
| Telehealth off-label subscription | $200-400 | $200-400 / mo | Includes consult + 4-8 doses per month; cheapest off-label path. |
| Specialty hormone clinic | $400-800 | $300-600 / mo | Higher pricing reflects broader protocol context and clinical depth. |
What to expect on PT-141 (Bremelanotide): your first weeks
Effect onset 30-45 minutes after subcutaneous injection.
Effect duration roughly 6-12 hours.
Most common side effects (nausea, flushing, headache) typically peak in the first 1-2 hours.
Clinical evidence behind PT-141 (Bremelanotide)
Vyleesi was FDA-approved based on phase-3 trials (RECONNECT 1 and 2) showing statistically significant improvement in sexual desire scores in premenopausal women with HSDD. Off-label evidence in men is more limited but supports use for desire-focused complaints. Long-term safety data exists from the on-label population.
PT-141 (Bremelanotide)side effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •Nausea (most common — affects 40%+ of patients in trials, typically mild)
- •Flushing and warm sensation
- •Headache
- •Injection-site reactions
- •Transient mild blood pressure elevation in first 1-2 hours
Who shouldn't take PT-141 (Bremelanotide)
- •Patients with uncontrolled hypertension
- •Patients with significant cardiovascular disease
- •Pregnancy or planning pregnancy
- •Concurrent use of melanocortin receptor antagonists or naltrexone
- •Patients with predisposition to melasma (PT-141 can darken pigmentation)
Eligibility for PT-141 (Bremelanotide)
- •Adult patients with desire-or-arousal-focused sexual complaint
- •Controlled blood pressure (PT-141 can transiently elevate BP)
- •No significant cardiovascular disease
- •Willingness to use on-demand rather than daily
PT-141 (Bremelanotide) samples: frequently asked
PT-141 vs sildenafil — which should I use?
Different mechanisms, different problems. Sildenafil acts on vascular tissue to enable mechanical erection; use it when the issue is achieving or maintaining erection despite normal desire. PT-141 acts on CNS arousal pathways; use it when the issue is desire/arousal regardless of mechanical function. Some patients use both together for layered effect.
Why does PT-141 cause nausea?
Melanocortin receptor agonism in the CNS produces nausea as a common side effect, particularly at higher doses or in PT-141-naive patients. Most patients adapt within the first few doses. Reducing dose or pre-treating with anti-nausea medication mitigates for sensitive patients.
Can PT-141 be compounded at a 503A pharmacy?
Generally no, for the same reason as tesamorelin — Vyleesi is the FDA-approved product on market, so 503A compounding requires specific clinical justification. Most US PT-141 access is via Vyleesi prescription (on or off label) rather than compounded.
How does PT-141 compare to other libido-focused approaches?
It's the only on-demand pharmacological agent specifically targeting the CNS arousal pathway. Hormone optimization (testosterone, thyroid) addresses underlying drivers; PT-141 addresses the acute arousal moment. Most clinical contexts use them complementarily.
Is PT-141 the same as Vyleesi?
Vyleesi is the brand name of the FDA-approved bremelanotide product (Cosette Pharmaceuticals). PT-141 is the original development code for bremelanotide and the name still used in research and off-label clinical contexts. They refer to the same molecule.